Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
Public ClinicalTrials.gov record NCT02891850. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Randomized, International, Multicenter, Double-arm, Controlled, Open-label Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Are on a Stable Dose of Phosphodiesterase-5 Inhibitors (PDE-5i) With or Without Endothelin Receptor Antagonist (ERA), But Not at Treatment Goal
Study identification
- NCT ID
- NCT02891850
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 225 participants
Conditions and interventions
Conditions
Interventions
- Riociguat (Adempas, BAY63-2521) Drug
- Sildenafil Drug
- Tadalafil Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 10, 2017
- Primary completion
- Jan 28, 2020
- Completion
- Mar 2, 2020
- Last update posted
- Feb 25, 2021
2017 – 2020
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85012 | — |
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | Orlando | Florida | 32803 | — |
| Not listed | Weston | Florida | 33331 | — |
| Not listed | Kansas City | Kansas | 66103 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Troy | Michigan | 48085 | — |
| Not listed | Newark | New Jersey | 07112 | — |
| Not listed | Mineola | New York | 11501 | — |
| Not listed | New York | New York | 10003 | — |
| Not listed | Rochester | New York | 14623 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Nashville | Tennessee | 37232 | — |
| Not listed | Dallas | Texas | 75390 | — |
| Not listed | Richmond | Virginia | 23225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02891850, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 25, 2021 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02891850 live on ClinicalTrials.gov.